HOME >> BIOLOGY >> NEWS
Blood markers may reflect newborns' potential of contracting HIV

Preventing HIV-infected pregnant women from transmitting the virus to their newborns has long been a major concern for obstetricians. As such, many doctors continue to debate the benefits of elective Caesarian section as a way to protect the infant.

In high-risk pregnancies, where the viral loads can't be suppressed with medication, delivering a baby by C-section directly from the protected, sterile environment of the amniotic sac can limit the risk of HIV transmission. But in lower-risk pregnancies, where antiretroviral medications keep the virus in check, the risk of transmitting HIV to a newborn is only about 1 percent to 2 percent.

A new study by researchers at Johns Hopkins and the National Institutes of Health demonstrates that uncomplicated labor and vaginal delivery does not stimulate the babies' immune systems. Results are scheduled to be presented Jan. 18 at the annual meeting of the Society for Maternal-Fetal Medicine in New Orleans.

A research team led by Hopkins obstetrician Helene Bernstein, M.D., Ph.D., studied lymphocytes from the umbilical cords of 23 babies born by vaginal delivery or elective C-section, as well as cells taken from eight babies born to mothers who had chorioamnionitis (a bacterial infection of the amniotic sac) or preterm labor.

None of the women had HIV. Checking for specific biochemical markers of white blood cell activation, they found the level of cell activity to be similar among babies born by either method. In addition, when HIV was introduced to these cells in the laboratory, there was no difference in their ability to be infected.

However, the babies born to mothers with chorioamnionitis or preterm labor did show activation of their white blood cells. When HIV was introduced to the white blood cells in the laboratory, there were more infections and the virus grew quickly, meaning that these infants could be at higher risk for HIV transmission if born to HIV-infected mothers with
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
18-Jan-2002


Page: 1 2

Related biology news :

1. Blood pressure hormone may inhibit growth of lung cancer
2. Blood tests identify patients on dialysis at high risk for death from cardiovascular disease
3. Blood banking systems improving in China, more progress needed
4. Blood proteins tied to inflammation
5. Bloodworms way with copper likely provides paradigm for new materials
6. Blood stem cells carry targeted genes
7. Blood vessels trigger development of the pancreas
8. Blood vessels found to signal chain of destruction in bone diseases
9. Blood markers associated with autism and mental retardation
10. Blood test for diagnosing schizophrenia
11. Blood pressure-lowering DASH diet also reduces homocysteine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
(Date:12/7/2016)... , Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dr. Dan Kephart as its chief science ... will assume his responsibilities at Neogen effective Jan. 1. ... director for the agribusiness unit of Thermo Fisher Scientific, ... at Life Technologies. His extensive industry experience also includes ...
Breaking Biology Technology:
Cached News: